ArticleFrontiers in neurology2024

Innovation and optimization in autoimmune encephalitis trials: the design and rationale for the Phase 3, randomized study of satralizumab in patients with NMDAR-IgG-antibody-positive or LGI1-IgG-antibody-positive autoimmune encephalitis (CIELO).

Soon-Tae Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.